Who is sponsoring NCT01434342?

NCT01434342 is sponsored by Wake Forest University Health Sciences.

What condition does NCT01434342 study?

NCT01434342 studies Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer.

What drugs are being tested in NCT01434342?

Interventions: Nicotine Replacement Patch.

What is the status of NCT01434342?

NCT01434342 is currently COMPLETED.

Last reviewed 2021-09-28 · How we verify

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

NCT01434342 EARLY_PHASE1 COMPLETED Results posted

RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population. Smoking reduces the efficacy of cancer treatments including surgery, radiation and chemotherapy. Despite the negative consequences, it is estimated that between 15-75% of patients with cancer continue to smoke after their cancer diagnosis. Lung, breast, prostate, colorectal, bladder, head \& neck, and cervical cancer patients were chosen because there is evidence of potential clinical benefit associated with quitting smoking in all of these populations and they represent a mix of both smoking and non-smoking related cancers.

Details

Lead sponsor	Wake Forest University Health Sciences
Phase	EARLY_PHASE1
Status	COMPLETED
Enrolment	146
Start date	Sat Oct 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jan 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Lung Cancer
Tobacco Use Disorder
Breast Cancer
Colorectal Cancer
Prostate Cancer

Interventions

Nicotine Replacement Patch

Countries

United States